Skip to main content
Toggle navigation
Login
Search
Home
iwCLL X / Twitter
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Favorite
Tweet
Rachel Bubik, PharmD
Department of Pharmacy, Mayo Clinic
N/A
Poster(s):
1160 - Clinical outcomes in patients with chronic lymphocytic leukemia (CLL) treated with venetoclax-based regimens
3004 - A Phase 2 Study of Minimal Residual Disease-Guided, Time-Limited, First-Line Therapy of Chronic Lymphocytic Leukemia with Pirtobrutinib and Venetoclax (MIRACLE)
